COMP <GO>
CON vs ABBV // EV/EBITDA & P/E VALUATION
Concentra Group Holdings Parent Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CON 6
— ABBV 8
▲ EV/EBITDA & P/E VALUATION LEADER: CON
LAST: $40.38 (-2.11%) • MKT CAP: $5.26B
valuation
15.4x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CON VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CON | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 19.70% | 29.00% | -9.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.4x | 33.3x | -17.90 | CON | /valuation <GO> |
| Free Cash Flow Yield | 3.75% | 3.47% | +0.28 | CON | /fcf-yield <GO> |
| Operating Margin | 15.40% | 24.60% | -9.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 6.90% | +0.80 | CON | /net-margins <GO> |
| Revenue Growth (YoY) | 13.90% | 8.60% | +5.30 | CON | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.61% | 2.27% | -1.66 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.53 | 5.33 | -2.80 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | CON | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.8 | 72.8 | -6.96 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.5x | 113.1x | -86.60 | CON | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.26B | $513.86B | -$508.60B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CON REV | ABBV REV | CON GROSS % | ABBV GROSS % | CON FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.16B | $61.16B | 44.0% | 70.2% | $197.1M | $17.82B |
| FY 2024 | $1.90B | $56.33B | 44.0% | 70.0% | $210.3M | $17.83B |
| FY 2023 | $1.84B | $54.32B | 44.0% | 44.0% | $151.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CON // BETA 1.00
ABBV // BETA 1.15